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AVE8062, a derivative of combretastatin A-4, has a strong stanching effect on tumour blood flow (TBF), which leads to complete
blockage of nutrient supply to solid tumours and their necrosis. Previously, we reported that TBF stasis is due to increased arteriolar
resistance caused by AVE8062 and a lasting decrease in perfusion pressure in tumour-feeding vessels. Here, we measured changes in
TBF in rat solid tumour LY80 during continuous administration of AVE8062-like epinephrine or four catecholamines that are unlike
AVE8062 (norepinephrine, dopamine, methoxamine, and metaraminol) to the region of increased vascular resistance. Venous
administration of 0.3mgml
 1 epinephrine caused TBF to fall immediately to near zero, where it remained throughout the
administration period. With a 30-min drug administration, TBF began to recover immediately when drug administration halted. With
a 60-min epinephrine administration, TBF recovered somewhat, but not to the previous level. With drug administration of 120min,
TBF did not recover during the subsequent 8h. Likewise, 0.1mgml
 1 epinephrine produced irreversible occlusion after 120min of
administration. In contrast, 120min of administration of the four other catecholamines resulted in no occlusion. Only the group given
0.3mgml
 1 epinephrine (not that given methoxamine) showed significantly greater necrosis than the control. We conclude that, for
epinephrine to cause irreversible occlusion of these vessels, a marked decrease in perfusion pressure in tumour-feeding blood vessels
is necessary and should be maintained for 2h. This conclusion is consistent with the previously demonstrated mechanism of
irreversible arteriole occlusion caused by AVE8062. AVE8062 and epinephrine appear to have the same mechanism of action
regarding induction of tumour blood flow stasis.
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AVE8062 (previous code name AC7700), a derivative of combre-
tastatin A-4, is reported to cause powerful stasis of tumour blood
flow (TBF) (Hori et al, 1999), thereby preventing nutrient supply to
the cancer and ultimately leading to necrosis of solid tumours
(Hori et al, 1999; Nihei et al, 1999a,b). Such effects are known for
subcutaneously transplanted mouse and rat tumours, autochtho-
nous primary tumours induced by chemical carcinogens (Hori
et al, 2001), tumours growing within internal organs (Hori et al,
2002; Ohno et al, 2002), lymph node metastases, small foci cancers,
and most solid tumours (Hori et al, 2002; Hori, 2003).
Previously, we showed by means of analysis of microcirculation
and intravital microscopic observations that the vascular occlusion
is not due to a direct effect of AVE8062 on tumour vessels, but
rather is likely due to an indirect effect on host arterioles (Hori and
Saito, 2003). Thus, AVE8062 causes a lasting increase in vascular
resistance of host arterioles, and this effect produces a marked and
persistent fall in the perfusion pressure of the downstream vessels
feeding the tumour. As a consequence, the lumens of many tumour
vessels become constricted or disappear entirely. Many red blood
cells then form aggregates in the lumens of drainage vessels, and
after 2–3h haemolysis of the red blood cells and subsequent
thrombosis occur. This is thought to be the irreversible process of
tumour vessel occlusion caused by AVE8062 (Hori and Saito,
2003).
If this microcirculatory mechanism is a general one, then drugs
other than AVE8062 that produce persistent blockage of blood
flow in tumour-feeding vessels should show irreversible TBF
stanching, similar to that caused by AVE8062. To test this
hypothesis, we measured the effect of five catecholamines:
epinephrine, norepinephrine, dopamine, and metaraminol on
tumour blood flow. Arteries can be clasiffied according to
Strahler’s method (1957): capillaries branching off from terminal
arterioles are assigned index number 1, terminal arterioles are
defined as a2; arterioles are then defined as a3, a4, a5 and so on, as
one proceeds from the periphery (Hori et al, 1990). Both AVE8062
and epinephrine raise the vascular resistance of host arterioles a3,
a4, and a5, and halt the blood flow in the downstream vessels that
feed the tumour (a2 vessels modified because of the influence of
the tumour) (Hori et al, 1993; Hori and Saito, 2003). In contrast,
methoxamine (Hori et al, 1993), norepinephrine, dopamine, and
metaraminol have less effect on vascular resistance in a3, a4, and
a5 vessels, and do not block blood flow in tumour-feeding vessels
(data not shown).
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that, when blood flow of tumour-feeding vessels is blocked for
a fixed time period by epinephrine, irreversible stanching of
blood flow to the tumour and widespread necrosis occur, similar to
the effects of AVE8062, and also that, when hypertensive
catecholamines, which cannot block the blood flow of tumour-
feeding vessels, such as norepinephrine, dopamine, methoxamine,
or metaraminol are used, occlusion of tumour vessels does not
occur.
MATERIALS AND METHODS
Rats and tumours
Male Donryu rats (Crj-Donryu; Nippon Charles-River, Yokohama,
Japan), 8–10 weeks old and with an average weight of 250–300g,
were used for all experiments. Rats were bred and maintained in a
ventilated, temperature-controlled (24711C), specific pathogen-
free environment, on a bed of wood shavings, with food and water
freely available and a 12-h light–dark cycle.
The tumour cell line LY80, which is a variant of Yoshida
sarcoma, was used. In our laboratory, this cell line is maintained
by successive i.p. transplantation. LY80 cells growing in ascites
of a donor rat were collected, suspended in phosphate-buffered
saline, and adjusted to a concentration of 2 10
6 cells per
0.1ml. Recipient rats were anaesthetised with diethyl ether
(Wako Pure Chemical Industries, Ltd, Osaka, Japan). Tumour
cells (2 10
6 cells) were implanted into the s.c. tissue of the back
of the rats.
Experiments were performed with the animals anaesthetised
in a temperature-controlled (24711C) box fitted with a suction
duct. All experimental protocols were reviewed by the Committee
on the Ethics of Animal Experiments in our institute, and
were carried out in accordance with Guidelines for Animal
Experiments issued by Tohoku University School of Medicine
and The Law (No. 105) and Notification (No. 6) issued by the
Japanese Government. The ethical guidelines that were followed
meet the standards required by the UKCCCR (Workman et al,
1998) guidelines.
Drugs
Epinephrine at 0.3 and 0.1mgml
 1 (Bosmin; Daiichi Pharmaceu-
tical Co., Ltd, Tokyo, Japan), 0.3mgml
 1 norepinephrine (Nor-
adrenaline; Sankyo Co., Ltd, Tokyo, Japan), 5mgml
 1 dopamine
(Inovan; Kyowa Hakko Kogyo Co., Tokyo, Japan), 2mgml
 1
methoxamine HCl (Mexan; Nippon Shinyaku Co., Ltd, Kyoto,
Japan), and 1mgml
 1 metaraminol bitartrate (Araminon; Banyu
Pharmaceutical Co., Ltd, Tokyo, Japan) were used as vasopressors.
A solution of 0.9% NaCl (Otsuka Pharmaceutical Co., Ltd, Tokyo,
Japan) was used as a control. Each drug was used at the
concentration at which systemic blood pressure increased to
150mmHg within 2min after the start of i.v. drug administration
at a rate of 0.015mlmin
 1.
Pentobarbital sodium salt (Tokyo Kasei Kogyo Co., Ltd, Tokyo,
Japan) and enflurane (Ethrane; Abbott Laboratories, North
Chicago, IL, USA) were given simultaneously for anaesthesia.
The pentobarbital powder was dissolved in distilled water to give a
concentration of 50mgml
 1, and was administered i.m. 10min
before the experiment at a dose of 30mgkg
 1. Supplemental doses
(15mgkg
 1 i.m.) were given at 90-min intervals to maintain
immobilisation. The enflurane concentration was kept at 1%
(vv
 1) in the inhaled carrier gas, which was provided at a rate of
1lmin
 1 by means of an anaesthetic apparatus for small
laboratory animals. We certify that this anaesthetic technique
did not change blood pressure or TBF significantly throughout the
experiment (Hori et al, 2002).
Measurement of TBF
TBF was measured by use of the hydrogen-clearance method (Hori
et al, 1991, 2002) that was originally developed by Aukland et al
(1964). The blood flow measured by this method is not the total
blood flow (Gullino and Grantham, 1961); rather, it is the local
blood flow (Peterson, 1979). In brief, after saturation of the tissue
with hydrogen by means of inhalation of 9% hydrogen gas in air
(at 1lmin
 1), the blood flow value (in mlmin
 1 per 100g tissue) in
a small region was calculated from the half-life of the clearance
curve obtained. A tissue blood flow metre with two separate
amplifiers (PHG-201; Unique Medical Co., Tokyo, Japan) was used.
Two 80-ı `m-diameter hydrogen electrodes (UHE-201C; Unique
Medical) and two rod-type Ag/AgCl reference electrodes (TT-
98012; Unique Medical) were usually used for each rat. The
reference electrodes were inserted between the skin and the
musculature in the caudal region.
TBF was measured 8–10 days after tumour implantation. For
this measurement, electrodes were inserted to a depth of 2mm
from the tumour surface. The drug was continuously infused
for 120min at a rate of 0.015mlmin
 1 by using a microinfusion
pump (Compact Syringe Pump; Harvard Apparatus Co., Inc.,
Millis, MA, USA). TBF was measured every 10min for 30min,
then every 30min for 1.5h, and thereafter every hour for 6h.
Throughout the experiment, rats were placed prone on a heated
stage at 341C and were kept in the same position. Rectal
temperature, monitored with a thermistor for small animals
(PTC-201; Unique Medical), was 33.5–35.51C and the condition
was maintained.
Measurement of mean arterial blood pressure
Mean arterial blood pressure (MABP) was monitored in all rats in
which TBF was measured. MABP was measured via a catheter (PE-
50; Becton Dickinson and Company, Sparks, MD, USA) inserted
into the right femoral artery. Pressure in the catheter was recorded
with a pressure transducer (TNF-R; Spectramed Medical Products,
Singapore), the output of which was fed into an amplifier (6M82;
NEC-Sanei Co., Tokyo, Japan) adapted for such measurement.
Histological examination
LY80 tumour-bearing rats were divided into three groups: I,
a group receiving 0.3mgml
 1. epinephrine solution (four rats); II,
a group receiving 2mgml
 1 methoxamine solution (four rats);
and III, a group receiving 0.9% NaCl solution (four rats). Each
solution was continuously infused for 120min into the tail vein
at a rate of 0.015mlmin
 1 by using a microinfusion pump
(Compact Syringe Pump; Harvard Apparatus). Rats in all groups
were killed with ether 48h after treatment. Each tumour was
resected for routine histology, fixed in 15% formalin, processed,
and embedded in paraffin. Sections of each tumour were cut
4mm thick and were stained with haematoxylin and eosin. The
area and distribution ratio of the necrotic regions were calculated
by using an area analyser (WT-4400SE, WACOM Co., Saitama,
Japan).
Statistics
All results are expressed as means7s.d. The statistical significance
for the change in TBF at each time point induced by each
vasoactive drug compared with that induced by 0.9% NaCl
solution was evaluated via the unpaired two-group t-test. The
occurrence of necrosis induced by the administration of epineph-
rine or methoxamine was also compared by using the unpaired
two-group t-test. P-values of 0.05 or lower were considered
statistically significant.
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Effect of continuous i.v. administration of epinephrine on
TBF and MABP
The changes in TBF during and after continuous i.v. administra-
tion of 0.3mgml
 1 epinephrine for 30, 60, and 120min, and of
0.1mgml
 1 epinephrine for 120min, compared with TBF change
during and after 0.9% NaCl administration are shown in Figure 1A.
TBF did not change at all by 0.9% NaCl. In contrast, TBF decreased
immediately and significantly (Po0.01) after the start of i.v.
administration of 0.3mgml
 1 epinephrine, and this level was
maintained during the continuous administration of the drug. In
the case of drug administration for 30min, the decreased TBF
started to recover immediately after the end of drug administration
and returned to the initial level approximately 90–120min later.
With 60min of drug administration, TBF began to recover
gradually beginning 60min after the end of drug administration.
However, TBF did not return to the initial level, even 8h later.
With 120min of drug administration, the TBF did not recover at all
throughout the experimental period, to 6h after the end of the
drug administration. Irreversible stasis of TBF was also observed at
the concentration of 0.1mgml
 1 epinephrine, with continuous
administration for 120min.
The change in MABP during and after continuous i.v.
administration of 0.3mgml
 1 epinephrine for 120min (seven
rats) is shown in Figure 1B. MABP was maintained at
150.177.5mmHg during the administration of the drug. However,
the increased MABP decreased immediately after the end of drug
administration.
Effect on TBF of continuous i.v. administration of four
catecholamines for 120min
Figure 2 indicates TBF changes during and after 120-min
continuous i.v. administration of 0.3mgml
 1 norepinephrine,
5mgml
 1 dopamine, 2mgml
 1 methoxamine, 1mgml
 1 metar-
aminol, or 0.9% NaCl solution. TBF in the methoxamine-treated
group significantly increased for 30min after the start of drug
administration compared with TBF in the 0.9% NaCl group
(Po0.01). TBF in the metaraminol-treated and dopamine-treated
groups significantly increased during drug administration, com-
pared with TBF in the 0.9% NaCl group (Po0.01). In contrast, TBF
in the norepinephrine-treated group significantly decreased by
approximately 50% throughout the experimental period of 8h
compared with TBF in the 0.9% NaCl group (Po0.01).
Histological examination
Figure 3 shows the typical histology of an LY80 tumour 48h after
continuous i.v. administration for 120min of 0.3mgml
 1 epi-
nephrine or 2mgml
 1 methoxamine, at a rate of 0.015mlmin
 1.
Extensive necrosis was found in the epinephrine-treated group
(Figure 3 A and B), but no large necrotic area was seen in
the methoxamine-treated group (Figure 3 C and D). The
percentage of necrosis in the maximum tumour section is shown
in Figure 4. The percentages of necrosis after treatment with
epinephrine (n¼4), methoxamine (n¼4), or 0.9% NaCl solution
(n¼4) were 79.775.9% (tumour area, 1.4370.37cm
2), 8.574.5%
(tumour area, 1.4770.20cm
2), and 9.678.1% (tumour area,
60
60
60
40
20
50
40
30
20
10
0
0
0
120
120
100
80
180
180
140
160
240 300 360 420 480
Time (min)
60 0 120 180 240 300 360 420 480
Time (min)
T
u
m
o
u
r
 
b
l
o
o
d
 
f
l
o
w
 
(
m
l
/
m
i
n
/
1
0
0
 
g
)
M
A
B
P
 
(
m
m
H
g
)
A
B
Figure 1 Changes in TBF and systemic pressure (MABP) caused by
epinephrine. (A) Changes in TBF after continuous administration of
epinephrine at a rate of 0.015mlmin
 1. J, 30-min administration of
0.3mgml
 1 epinephrine (n¼10); K, 60-min administration of 0.3mgml
 1
epinephrine (n¼10); &, 120-min administration of 0.3mgml
 1 epinephr-
ine (n¼14); ’, 120-min administration of 0.1mgml
 1 epinephrine
(n¼10); W, 0.9% NaCl solution (n¼12). Continuous administration
began at time 0. (B) Changes in systemic pressure caused by 120-min
continuous administration of 0.3mgml
 1 epinephrine.
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Figure 2 Changes in TBF after 120min of continuous administration of
various catecholamines: J, 0.3mgml
 1 norepinephrine (n¼10); K,
5mgml
 1 dopamine (n¼8); &, 2mgml
 1 methoxamine (n¼11); ’,
1mgml
 1 metaraminol (n¼10); W, 0.9% NaCl solution (n¼12, identical
with Figure 1).
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2), respectively. Highly significant necrosis was thus
observed in the epinephrine-treated group (epinephrine vs
methoxamine and epinephrine vs 0.9% NaCl, both at Po0.001).
The difference between the methoxamine-treated group and the
control group was not significant, however. On the other hand,
epinephrine showed no histological effects on normal tissues
under the condition described above (data not shown).
DISCUSSION
In the present study, we showed that, when a marked decrease in
perfusion pressure in tumour-feeding vessels is brought about with
the use of epinephrine, vascular blood flow stanching becomes
irreversible after 2h, which leads to widespread necrosis within the
tumour. Since cultures of LY80 cells grown in a medium
containing 0.03–0.3mgml
 1 epinephrine for more than 2h did
not show any decrease in cancer cell viability (data not shown), we
conclude that the epinephrine-induced tumour necrosis was
clearly a consequence of the effect of epinephrine on tumour
microcirculation.
Clinically, epinephrine is currently used during resuscitation
following cardiac arrest or for treatment of anaphylaxis. In the
field of cancer research, epinephrine is known to reduce TBF (Li
et al, 1990; Hori et al, 1993). Moreover, in pharmacoangiography,
which exploits the different responses of tumour tissue and normal
tissue, attempts at improving the diagnostic image by using
epinephrine had been reported long ago (Abrams, 1964). The
ability of epinephrine to induce selective tumour necrosis by
means of continuous administration has not previously been
reported, and is thought to be the principal new finding of the
present study.
This conclusion was made deductively on the basis of analysis of
haemodynamic mechanisms leading to the necrosis of solid
tumours by the derivative of combretastatin A-4, that is,
Figure 3 Effects of continuous administration of epinephrine or methoxamine on tumour tissue. (A,B) show the effects of epinephrine; (C,D) show
those of methoxamine. (A,C) show 200-fold magnifications; bars, 100mm. (B,D) show 400-fold magnifications; bars, 50mm.
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Figure 4 Percentage of necrosis 48h after continuous administration of
epinephrine or methoxamine. A significant difference in necrosis was not
found between the methoxamine and 0.9% NaCl-treated groups, but there
was a significant increase in necrosis in the epinephrine-treated grouped
compared with the methoxamine-treated and 0.9% NaCl-treated groups.
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in systemic blood pressure (Hori et al, 1999), similar to that
produced by epinephrine, but the hypertension itself does not
cause the stanching of TBF. In methoxamine, dopamine, and
metaraminol, there was no stanching effect even after 120min of
continuous drug administration and did not induce necrosis of
tumour tissue. Whether stasis of TBF occurs depends on which
arterioles show increases in vascular resistance. The present study
achieved the clarification of this point. However, it is not yet clear
from the present studies as to why methoxamine, dopamine, and
metaraminol have a lesser effect on the a3, a4, and a5 arterioles.
Although the sites at which AVE8062 and epinephrine facilitate
the increase in vascular resistance are similar, the decisive
difference between these two agents is the duration of their effects.
The effects of AVE8062, after one-shot administration, persisted
for 2–3h (Hori et al, 1999), whereas the effects of epinephrine
disappeared immediately when administration was halted. We
therefore hypothesised that, if the duration of epinephrine-induced
increased vascular resistance would approach that of AVE8062,
epinephrine should also bring about tumour necrosis in a manner
similar to that of AVE8062. We consequently investigated the
effects of 30, 60, and 120min of continuous administration of
epinephrine on changes in blood flow to tumour tissue. We found
that TBF began to recover immediately after cessation of 30min of
epinephrine administration, whereas, after a 60-min administra-
tion, the TBF showed some recovery, but not to its original level.
After 120min of epinephrine administration, however, TBF did not
recover and the stasis was irreversible. Moreover, similar to
AVE8062, epinephrine induced extensive intratumour necrosis.
Noteworthy is the fact that, although a dosage of 0.3mgml
 1
epinephrine delivered during 60min did not produce irreversible
occlusion of tumour blood vessels, a lower dosage, 0.1mgml
 1,
delivered for 120min did produce irreversible effects. This fact
demonstrates that the total amount of epinephrine administered is
not important, but the duration of administration is.
With regard to tumour growth inhibition, epinephrine was
notably weaker than AVE8062 (data not shown). Epinephrine had
antitumour effects related solely to its occlusive effects, whereas
AVE8062 not only occluded tumour blood vessels but was also
thought to inhibit tubulin polymerisation in tumour cells. This fact
suggests that the tumoricidal effects of epinephrine could be
significantly enhanced by administration of epinephrine together
with appropriate anticancer drugs.
As for the mechanism by which AVE8062 constricts host
arterioles, the present research does not provide definite answers.
Nevertheless, because the effects of AVE8062 on microcirculation
are extremely similar to those of epinephrine, it is likely that both
agents affect vascular smooth muscle tissue. Thus, a molecular-
level study will be necessary to determine whether a specific
receptor exists for AVE8062 or whether the effects on vascular
resistance brought about by AVE8062 involve the epinephrine-
activated alpha receptor.
From the present results concerning these catecholamines, we
can conclude that the conditions necessary for bringing about
irreversible occlusion of TBF are as follows: (i) marked reduction
of perfusion pressure of vessels feeding the tumour, and (ii)
maintenance of hemodynamic stasis for at least 2h. AVE8062 and
epinephrine appear to have the same mechanism of action
regarding induction of tumour blood flow stasis.
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